

Sheet 1 of 3

STYLING SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/111001 10/595,062 Ni et al. January 25, 2006 Not Yet Assigned May 9, 2006
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,013,241	01/11/2000	Marchal et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Ballester et al., "Indium-111-Monoclonal Antimyosin Antibody Studies After the First Year of Heart Transplantation. Identification of Risk Groups for Developing Rejection During Long-Term Follow-Up and Clinical Implications." <i>Circulation</i> 82:2100-2107 (1990).					
	Bormans et al., "Preparation, Analysis and Biodistribution in Mice of Iodine-123 Labelled Derivatives of Hypercin." <i>J. Label. Compd. Radiopharm.</i> 47:191-198 (2004).					
	Bremerich et al., "Microvascular Injury in Reperfused Infarcted Myocardium: Noninvasive Assessment with Contrast-Enhanced Echoplanar Magnetic Resonance Imaging." <i>J. Am. Coll. Cardiol.</i> 32:787-793 (1998).					
	Buja et al., "Sites and Mechanisms of Localization of Technetium-99m Phosphorus Radiopharmaceuticals in Acute Myocardial Infarcts and other Tissues." <i>J. Clin. Invest.</i> 60:724-740 (1977).					
	Chen et al., "Photodynamic Therapy with Hypercin in a Mouse P388 Tumor Model: Vascular Effects Determine the Efficacy." <i>Int. J. Oncol.</i> 18:737-742 (2001).					
	Choi et al., "Irreversibly Damaged Myocardium at MR Imaging with a Necrotic Tissue-Specific Contrast Agent in a Cat Model." <i>Radiology</i> 215:863-868 (2000).					
	Dec et al., "Antimyosin Antibody Cardiac Imaging: Its Role in the Diagnosis of Myocarditis." <i>J. Am. Coll. Cardiol.</i> 16:97-104 (1990).					
	Flotats and Carriló, "Non-Invasive In Vivo Imaging of Myocardial Apoptosis and Necrosis." <i>Eur. J. Nucl. Med. Mol. Imaging</i> 30:615-630 (2003).					
	Frist et al., "Noninvasive Detection of Human Cardiac Transplant Rejection with Indium-111 Antimyosin (Fab) Imaging." <i>Circulation</i> 76:V81-V85 (1987).					

EXAMINER /Leah Schlientz/	DATE CONSIDERED 12/30/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/11001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/595,062
		Applicant	Ni et al.
		Filing Date	January 25, 2006
		Group	Not Yet Assigned
(37 C.F.R. § 1.98(b))		IDS Filed	May 9, 2006

	Herijgers et al., "Localization and Determination of Infarct Size by Gd-Mesoporphyrin Enhanced MRI in Dogs," <i>Int. J. Card. Imaging</i> 13:499-507 (1997).
	Khaw et al., "Specificity of Localization of Myosin-Specific Antibody Fragments In Experimental Myocardial Infarction. Histologic, Histochemical, Autoradiographic and Scintigraphic Studies," <i>Circulation</i> 60:1527-1531 (1979).
	Khaw et al., "Myocardial Injury: Quantitation by Cell Sorting Initiated with Antimyosin Fluorescent Spheres," <i>Science</i> 217:1050-1053 (1982).
	Khaw et al., "Scintigraphic Quantification of Myocardial Necrosis in Patients After Intravenous Injection of Myosin-Specific Antibody," <i>Circulation</i> 74:501-508 (1986).
	Khaw et al., "Acute Myocardial Infarct Imaging with Indium-111-Labeled Monoclonal Antimyosin Fab," <i>J. Nucl. Med.</i> 28:1671-1678 (1987).
	Khaw et al., "Avidity of Technetium 99m Glucarate for the Necrotic Myocardium: In Vivo and In Vitro Assessment," <i>J. Nucl. Cardiol.</i> 4:283-290 (1997).
	Khaw, "The Current Role of Infarct Avid Imaging," <i>Semin. Nucl. Med.</i> 29:259-270 (1999).
	Lavie et al., "The Chemical and Biological Properties of Hypericin — A Compound with a Broad Spectrum of Biological Activities," <i>Med. Res. Rev.</i> 15:111-119 (1995).
	Lee et al., "MR Imaging of Reperfused Myocardial Infarction: Comparison of Necrosis-Specific and Intravascular Contrast Agents in a Cat Model," <i>Radiology</i> 226:739-747 (2003).
	Lim and Choi, "MRI of Myocardial Infarction," <i>J. Magn. Reson. Imaging</i> 10:686-693 (1999).
	Marchal et al., "Paramagnetic Metalloporphyrins: Infarct Avid Contrast Agents for Diagnosis of Acute Myocardial Infarction by MRI," <i>Eur. Radiol.</i> 6:2-8 (1996).
	Maurer et al., "Contrast-Enhanced High Resolution Magnetic Resonance Imaging of Pigmented Malignant Melanoma Using Mn-TPPS ₄ and Gd-DTPA: Experimental Results," <i>Melanoma Res.</i> 10:40-46 (2000).
	Narula et al., "Recognition of Acute Myocarditis Masquerading as Acute Myocardial Infarction," <i>N Engl. J. Med.</i> 328:100-104 (1993).
	Narula et al., "Very Early Noninvasive Detection of Acute Experimental Nonreperfused Myocardial Infarction with ^{99m} Tc-Labeled Glucarate," <i>Circulation</i> 95:1577-1584 (1997).
	Nelson et al., "Metalloporphyrins as Tumor-Seeking MRI Contrast Media and as Potential Selective Treatment Sensitizers," <i>Invest. Radiol.</i> 25:S71-S73 (1990).
	Ni et al., "Localization of Metalloporphyrin-Induced 'Specific' Enhancement in Experimental Liver Tumors: Comparison of Magnetic Resonance Imaging, Microangiographic, and Histologic Findings," <i>Acad. Radiol.</i> 2:687-699 (1995).

EXAMINER	/Leah Schlientz/	DATE CONSIDERED	12/30/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50304/111001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/595,062
		Applicant Ni et al.
		Filing Date January 25, 2006
		Group Not Yet Assigned
(37 C.F.R. § 1.98(b))		IDS Filed May 9, 2006

	Ni et al., "Paramagnetic Metalloporphyrins: From Enhancers of Malignant Tumors to Markers of Myocardial Infarcts," <i>Acad. Radiol.</i> 3:S395-S397 (1996).
	Ni et al., "Evaluation of Interventional Liver Tumor Ablation with Gd-Mesoporphyrin Enhanced Magnetic Resonance Imaging (Oral)," <i>Radiology</i> 205:319(757) (1997).
	Ni et al., "Magnetic Resonance Imaging — Histomorphologic Correlation Studies on Paramagnetic Metalloporphyrins in Rat Models of Necrosis," <i>Invest. Radiol.</i> 32:770-779 (1997).
	Ni et al., "Validation of Intracoronary Delivery of Metalloporphyrin as an In Vivo 'Histochemical Staining' for Myocardial Infarction with MR Imaging," <i>Acad. Radiol.</i> 5:S38-S41 (1998).
	Ni et al., "MRI Contrast Enhancement of Necrosis by MP-2269 and Gadophrin-2 in a Rat Model of Liver Infarction," <i>Invest. Radiol.</i> 36:97-103 (2001).
	Ni et al., "Occlusive Myocardial Infarction Enhanced or Not Enhanced with Necrosis-avid Contrast Agents at MR Imaging," <i>Radiology</i> 225:603-606 (2002).
	Obrador et al., "Active Myocardial Damage Without Attending Inflammatory Response in Dilated Cardiomyopathy," <i>J. Am. Coll. Cardiol.</i> 21:1667-1671 (1993).
	Obrador et al., "Presence, Evolving Changes, and Prognostic Implications of Myocardial Damage Detected in Idiopathic and Alcoholic Dilated Cardiomyopathy by 111In Monoclonal Antimyosin Antibodies," <i>Circulation</i> 89:2054-2061 (1994).
	Okada et al., "Early Detection of Infarct in Reperfused Canine Myocardium Using ^{99m} Tc-Glucarate," <i>J. Nucl. Med.</i> 45:655-664 (2004).
	Olmos et al., "High Sensitivity of Radiolabelled Antimyosin Scintigraphy in Assessing Anthracycline Related Early Myocyte Damage Preceding Cardiac Dysfunction," <i>Nucl. Med. Commun.</i> 23:871-877 (2002).
	Pass, "Photodynamic Therapy in Oncology: Mechanisms and Clinical Use," <i>J. Natl. Cancer Inst.</i> 85:443-456 (1993).
	Pislaru, "Noninvasive Measurements of Infarct Size After Thrombolysis with a Necrosis-Avid MRI Contrast Agent," <i>Circulation</i> 99:690-696 (1999).
	Rude et al., "Clinical Implications of the Technetium-99m Stannous Pyrophosphate Myocardial Scintigraphic 'Doughnut' Pattern in Patients with Acute Myocardial Infarcts," <i>Circulation</i> 59:721-730 (1979).
	Saeed et al., "Reperfused Myocardial Infarction as Seen with Use of Necrosis-Specific versus Standard Extracellular MR Contrast Media in Rats," <i>Radiology</i> 213:247-257 (1999).
	Wendland et al., "Contrast-Enhanced MRI for Quantification of Myocardial Viability," <i>J. Magn. Reson. Imaging</i> 10:694-702 (1999).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

EXAMINER	/Leah Schlientz/	DATE CONSIDERED	12/30/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			